Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Abstract

The most severe sequelae after rehabilitation from SARS are femoral head necrosis and pulmonary fibrosis. We performed a 15-year follow-up on the lung and bone conditions of SARS patients. We evaluated the recovery from lung damage and femoral head necrosis in an observational cohort study of SARS patients using pulmonary CT scans, hip joint MRI examinations, pulmonary function tests and hip joint function questionnaires. Eighty medical staff contracted SARS in 2003. Two patients died of SARS, and 78 were enrolled in this study from August 2003 to March 2018. Seventy-one patients completed the 15-year follow-up. The percentage of pulmonary lesions on CT scans diminished from 2003 (9.40 ± 7.83)% to 2004 (3.20 ± 4.78)% ( P < 0.001) and remained stable thereafter until 2018 (4.60 ± 6.37)%. Between 2006 and 2018, the proportion of patients with interstitial changes who had improved pulmonary function was lower than that of patients without lesions, as demonstrated by the one-second ratio (FEV 1 /FVC%, t = 2.21, P = 0.04) and mid-flow of maximum expiration (FEF 25%–75% , t = 2.76, P = 0.01). The volume of femoral head necrosis decreased significantly from 2003 (38.83 ± 21.01)% to 2005 (30.38 ± 20.23)% ( P = 0.000 2), then declined slowly from 2005 to 2013 (28.99 ± 20.59)% and plateaued until 2018 (25.52 ± 15.51)%. Pulmonary interstitial damage and functional decline caused by SARS mostly recovered, with a greater extent of recovery within 2 years after rehabilitation. Femoral head necrosis induced by large doses of steroid pulse therapy in SARS patients was not progressive and was partially reversible.

Cited by papers we hold 10

• Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19 · 2021
  No notice
• Virus infection induced pulmonary fibrosis · 2021
  No notice
• Lung Fibrosis after COVID-19: Treatment Prospects · 2021
  No notice
• COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts · 2021
  No notice
• Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 · 2021
  No notice
• Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity · 2021
  No notice
• COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection · 2020
  No notice
• Short- and potential long-term adverse health outcomes of COVID-19: a rapid review · 2020
  No notice
• Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies · 2020
  No notice
• SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.